Clinical trial
A Phase 2 Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL)
NCT00866047 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL)
- Lead sponsor
- Seagen Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2009
- Completion date
- June 30, 2016
- Enrollment
- 58 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.